Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH

Nov 16, 2020

Montreal, Canada – November 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

Results from a new proteomics sub-analysis presented by Dr. Fourman show that serum levels of three proteins associated with the development of Nonalcoholic Steatohepatitis (NASH) and fibrosis, Vascular Endothelial Growth Factor A (VEGFA), Transforming Growth Factor Beta 1 (TGFβ1) and Colony Stimulating Factor 1 (CSF1), were significantly reduced in tesamorelin patients compared to the placebo group. Specifically, the difference in serum levels, consistent with downregulation in hepatic gene expression, of VEGFA was log2-fold, -0.24 (p=0.03), TGFβ1 was log2-fold -0.31 (p=0.03) and CSF1 log2-fold -0.19 (p=0.004).